• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias
Ideally, dementia care should be provided by a collaborative team. Eligible patients should be treated with the cognitive-enhancing medications, the cholinesterase inhibitors and memantine. For most of the common causes of dementia, there are no disease-modifying medications, with the exception that vascular dementia can be prevented by treating vascular risk factors to prevent stroke. There is hope that Alzheimer disease can be treated by using monoclonal antibodies that target amyloid beta, although more trials are needed. Holistic, patient-centered care can enhance quality and extend the time that the patient can live s...
Source: Clinics in Geriatric Medicine - October 18, 2022 Category: Geriatrics Authors: Landon Perlett, Eric E. Smith Source Type: research

Beneficial effects of memantine on ischemia/reperfusion injury following torsion/detorsion induced testicular damage in rats: Improvement in histological and biochemical parameters
Testicular torsion is a common urologic emergency and one of the causes of infertility in males. Hence, prompt diagnosis and treatment are important to prevent testicular damages. It has been reported that memantine, a drug for Alzheimer's disease has anti-oxidative role against cerebral ischemic stroke and cardiac ischemia reperfusion.
Source: Journal of Pediatric Urology - April 28, 2021 Category: Urology & Nephrology Authors: Abbas Jafari, Hojat Ghasemnejad-Berenji, Mohadeseh Nemati, Sarvin Pashapour, Sonia Sadeghpour, Morteza Ghasemnejad-Berenji Source Type: research

Correlation of stroke and dementia with death: A study from the Swedish dementia registry
(Bentham Science Publishers) Patients who died of IS the most common type of dementia was vascular dementia while those died from other causes were most often diagnosed with Alzheimer's dementia (AD). Patients who died from IS and were registered in Riksstroke had higher MMSE score compared to other groups. Patients who died from IS took more cardiovascular medications. There were no differences in the use of antipsychotics, antidepressants, acetylcholinesterase inhibitors, memantine, anxiolytics, or hypnotics between the groups.
Source: EurekAlert! - Medicine and Health - December 14, 2018 Category: International Medicine & Public Health Source Type: news

Stroke as a cause of death in death certificates of patients with dementia: a cohort study from the Swedish Dementia Registry.
CONCLUSIONS: There was relatively high number of patients that died from IS in their death certificate but had not been registered in Riksstroke in the year before death. This creates concerns on the accuracy of death certificate stroke diagnoses, particularly for deaths taking place outside of hospitals. PMID: 30280666 [PubMed - as supplied by publisher]
Source: Current Alzheimer Research - October 2, 2018 Category: Neurology Authors: Subic A, Zupanic E, von Euler M, Norrving B, Cermakova P, Religa D, Winblad B, Kramberger MG, Eriksdotter M, Garcia-Ptacek S Tags: Curr Alzheimer Res Source Type: research

Memantine protects against ischemia/reperfusion ‐induced brain endothelial permeability
In conclusion, our results identified a novel function of memantine in maintaining brain vascular barrier function and suggested that memantine might be a potential therapeutic agent for the treatment of stroke. © 2018 IUBMB Life, 2018
Source: IUBMB Life - March 15, 2018 Category: Research Authors: Yingying Liu, Yudiao Huang, Yueyue Xu, Peng Qu, Minghua Wang Tags: Research Communication Source Type: research

Pharmacotherapy for Vascular Cognitive Impairment
AbstractVascular cognitive impairment (VCI) is the second most common type of dementia after Alzheimer ’s disease (AD). Stroke and cardiovascular risk factors have been linked to both AD and VCI and potentially can affect cognitive function in mid and later life. Various pharmacological agents, including donepezil, galantamine, and memantine, approved for the treatment of AD have shown modest cogni tive benefits in patients with vascular dementia (VaD). However, their functional and global benefits have been inconsistent. Donepezil has shown some cognitive benefit in patients with VaD only, and galantamine has shown some...
Source: CNS Drugs - August 7, 2017 Category: Neurology Source Type: research

A beacon of hope in stroke therapy—Blockade of pathologically activated cellular events in excitotoxic neuronal death as potential neuroprotective strategies
Publication date: Available online 17 February 2016 Source:Pharmacology & Therapeutics Author(s): Ashfaqul Hoque, M. Iqbal Hossain, S. Sadia Ameen, Ching-Seng Ang, Nicholas Williamson, Dominic C.H. Ng, Anderly Chueh, Carli Roulston, Heung-Chin Cheng Excitotoxicity, a pathological process caused by over-stimulation of ionotropic glutamate receptors, is a major cause of neuronal loss in acute and chronic neurological conditions such as ischaemic stroke, Alzheimer's and Huntington's diseases. Effective neuroprotective drugs to reduce excitotoxic neuronal loss in patients suffering from these neurological co...
Source: Pharmacology and Therapeutics - February 29, 2016 Category: Drugs & Pharmacology Source Type: research

Alzheimer's Drug May Enhance Stroke Recovery Alzheimer's Drug May Enhance Stroke Recovery
Memantine may improve stroke outcomes in a non-neuroprotective way, preliminary research suggests. Medscape Medical News
Source: Medscape Today Headlines - August 5, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Stroke Rounds: Dementia Drug for Stroke Recovery?
(MedPage Today) -- The Alzheimer's disease drug memantine (Namenda) might be worth a look for improving recovery from stroke, a mouse-model study suggested.
Source: MedPage Today Cardiovascular - July 22, 2014 Category: Cardiology Source Type: news

Memantine Enhances Recovery From Stroke Basic Sciences
Conclusions— Our results suggest that memantine improves stroke outcomes in an apparently non-neuroprotective manner involving increased brain-derived neurotrophic factor signaling, reduced reactive astrogliosis, and improved vascularization, associated with improved recovery of sensory and motor cortical function. The clinical availability and tolerability of memantine make it an attractive candidate for clinical translation.
Source: Stroke - June 23, 2014 Category: Neurology Authors: Lopez-Valdes, H. E., Clarkson, A. N., Ao, Y., Charles, A. C., Carmichael, S. T., Sofroniew, M. V., Brennan, K. C. Tags: Animal models of human disease, Imaging, Other imaging, Other Stroke Treatment - Medical Basic Sciences Source Type: research

Memantine for Lewy Body Disorders: Systematic Review and Meta-Analysis.
CONCLUSION: Our results suggest that memantine did not have a benefit for the treatment of Lewy body disorders in cognition and motor function. However, memantine may be superior to placebo for the overall impression of the disorders. Further, memantine is well tolerated. PMID: 24406251 [PubMed - as supplied by publisher]
Source: The American Journal of Geriatric Psychiatry - January 11, 2014 Category: Psychiatry Tags: Am J Geriatr Psychiatry Source Type: research